

Community pharmacists' counseling practices and patient experiences about topical corticosteroids – an online survey in the Klang Valley, Malaysia

Abigail Dayang Nathan

International Medical University

Pathiyil Ravi Shankar

International Medical University

Chandrashekhar T Sreeramareddy (✉ chandrashekharats@yahoo.com)

International Medical University

Research Article

Keywords: community pharmacist, counselling, topical corticosteroid

Posted Date: May 13th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1634168/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

Community Pharmacists (CPs) play an important role in patient counselling regarding the use of topical corticosteroids. We assessed the CP's self-reported counselling practices regarding topical corticosteroids and patients' reported counselling experiences.

Methods

A previously developed questionnaire was adapted to the Malaysian context. A random sample of 364 registered CPs practicing in three states Selangor, Kuala Lumpur, and Putrajaya were invited for an online survey. CPS questionnaire covered CPS's perceived patient knowledge about topical corticosteroid (TCS) use, CPs counseling practices, and their perceived barriers to counselling. Thirty patients were also selected from five pharmacies i.e., six consecutive patients who consulted each CP were invited to participate in the patient survey by completing a checklist about their experiences regarding the counselling received.

Results

A majority (> 90%) of the CPs most of the time explained to the patients that medication was TCS and frequency and duration of application but only 10% correctly identified scenarios needing medical referrals. Only about half of the CPs always explained about side effects, strength, efficacy, and storage of TCS. The two main barriers were patients' negative perception of TCS (65.4%) and pharmacists' lack of time for counselling (49.7%). Counselling practice score was associated with CPs age (aOR 0.86, 95%CI 0.78–0.94), pharmacists' recommendation on TCS use (aOR 0.11, 95%CI 0.02–0.61), and time spent on counselling (aOR 1.42, 95%CI 1.13–1.64).

Conclusion

CPs counselling practices to their patient about the use of TCS requires improvement. Continuing education and hands-on training are needed for CPs regarding counselling about TCS use.

Background

Community pharmacists, also known as retail pharmacists, play a significant role in primary health care delivery. They provide services such as supplying medication, providing medication review, and medical and lifestyle counseling. Studies have demonstrated that utilizing CPs for the treatment of minor ailments results in optimizing health resources and reducing congestion at primary health facilities [1]. Services provided by CPS have been shown to improve patient care and health outcomes [2, 3]. Strand et al. posit that pharmacists have the potential to contribute to and enhance population health [4]. In Malaysia, in addition to providing general medication counselling and health promotion services, CPs are also authorized to supply non-prescription Group C poisons to consumers as per the Poison Act 1952 [5]. The first schedule to the poisons list classifies medicines into part 1, part 2, and exempt categories; type 1 is further subdivided into groups A, B, C, and D [6].

Topical corticosteroids (TCS) are included under Group C poisons, making it a common medication prescribed and sold in private healthcare facilities, including community pharmacies [7]. During the counselling session, the frequency and dosage of application should be communicated effectively, for example, TCS is applied as a thin layer once or twice a day, depending on potency and formulation, and the dosage is expressed as a 'fingertip unit'[8]. Current clinical practice guidelines recommend the use of TCS as an adjunct with other treatments such as emollients, antibiotics, or antifungal topical medications, as well as with systemic therapy with antibiotics, antihistamines, or oral steroids where appropriate [9]. Improper use of TCS can aggravate an underlying superficial fungal or bacterial infection of the skin and prolonged exposure may result in skin thinning, striae, hyper- or hypopigmentation, hirsutism, and short stature in children or Cushing's syndrome [10]. Therefore, correct information provided to the patients about TCS is very important and CPs have an important role to play when they dispense TCS to the patients at the pharmacies.

CPs have the knowledge to advise patients and caregivers on optimum TCS use, and the provision of optimum and good quality counselling by CPs is associated with better treatment outcomes [11]. The key factors associated with the quality of counselling and the role CPs play in encouraging high-quality counselling practices are vital to ensure patients' safe and effective use of TCS. A previous study conducted in Portugal identified that less than 18.2% of patients received information on dosage, frequency, and duration for the application of the topical medication [12]. While studies have been conducted on the use of topical medications among patients with psoriasis [13] and on pharmacists' knowledge about the use of topical antibacterials in Malaysia [14], the counselling practices of TCS have previously not been studied. We aimed to assess the counselling practices of the community pharmacists regarding the use of TCS and determine the factors associated with counselling practices. We also studied patient experience with counselling received from CP about TCS.

Methods

Design, setting, and participants

A cross-sectional online survey was conducted among community pharmacists practicing in three Malaysian states (Selangor state, and the federal territories of Kuala Lumpur, and Putrajaya). Community pharmacists holding Type A license certification and currently working in community pharmacies were involved.

Type A license is issued by the pharmacy enforcement at the state level and allows a pharmacist to import, store and deal generally all poisons by wholesale and retail or by wholesale only or by retail only [16].

Study size

The sample size for CPs was determined using the formula for finite population. The expected proportion was 0.5. Proportion who had correct knowledge and practiced correct counselling technique was not available from the literature. For a confidence limit of 95% and 5% allowable error, the calculated minimum sample size was 303. Taking into consideration an anticipated non-response rate of 20%, the final sample size was 364.

Sampling methods

A list of 1,207 community pharmacists' holding licenses from Selangor and 601 from Kuala Lumpur and Putrajaya was obtained from the Official Portal of Pharmaceutical Services Programme [17]. Names and type of licenses were filtered to verify addresses, eliminate duplicates, and exclude those employed in private hospitals, compounding pharmacies, and veterinary pharmacies. After screening, a final list of community pharmacists holding type A license was created. The list had 925 CPs from Selangor and 473 from Kuala Lumpur and Putrajaya. From this list the CPs were selected for the survey by systematic sampling. From the required sample size of 364 participants, 60% were from Selangor (218) and the remaining 40% were from Kuala Lumpur and Putrajaya (146). Sampling interval was approximately four ($925/218 = 4.2$) for Selangor and ($473/146 = 3.3$) three for Kuala Lumpur and Putrajaya.

Questionnaire

The questionnaire for CPs was adapted with permission from the original questionnaire developed by Kang et al. [11]. The questionnaire (appendix 1) consisted of four sections. Section A collected information about socio-demographic characteristics of pharmacists, dispensing and sales of TCS in their pharmacy. Section B focused on type, and time taken to counsel and the extent to which various aspects of TCS use were covered and the respondent's perceived barriers to counselling. Section C covered questions about CPs perception of the patient's knowledge on TCS prior to the counselling. Section D assessed CPs knowledge about adverse drug events related to TCS. The original questionnaire was modified to suit local product formulations and dispensing practices. Other modifications such as questions on ethnicity and options for current workplace location were altered. The questionnaire was pilot tested among participants recruited using purposeful and snowball sampling. The Cronbach's alpha value obtained after the pilot test was 0.69.

Variables

Independent variables were socio-demographic characteristics as age, gender, work location, work status, years of experience as a community pharmacist, and education level. Dependent variables were CPs' perception regarding patients' knowledge about TCS measured using eight "yes/ no" type questions. The score for CPs perceived patient's knowledge of TCS was by adding the responses to eight items. The response options as 'yes' or 'no' were coded as '1' and '0' respectively. The score on CPs counselling practices on TCS use was measured using an 11-item, 3-point Likert scale (explain most of the time, explain half the time and did not explain most of the time scored as '2', '1', and '0' respectively). The sum of scores represents the counselling practice scores (maximum score of 22).

Data Collection

Due to the Coronavirus (COVID-19) pandemic, an online questionnaire was distributed from September to December 2021. Selected pharmacists were contacted using the email addresses or premise phone numbers listed on the pharmaceutical services website or obtained following a Google search, or via social media platforms such as Facebook or LinkedIn. Following personal contact with participants, the information sheet and questionnaire were delivered through email, or a link supplied via WhatsApp, Facebook, or LinkedIn messages. Participants who completed the questionnaire received RM5 (approx. USD 1.25) e-vouchers as a token of appreciation.

Patient study

CPs who participated in the online survey were requested to recruit patients who came to purchase TCS. Five of the CPs agreed to recruit patients for the study. From each of the five selected pharmacies six consecutive consenting patients were selected. The questionnaire for patients was extracted and modified from Question 12 in the original Kang et al. questionnaire [11]. The questionnaire comprised of six items about if the patient had received a specific component of counselling during the consultation with CPs. The response options were 'yes' or 'no' questions (appendix 2). Modifications were made to ensure layperson terms were used for the benefit of patients answering the questionnaire. The English language survey was also translated into the Malay language following standard recommended practices.

The self-administered survey questionnaire was anonymous. Patients visiting the selected community pharmacy to purchase a TCS were invited to answer a self-administered anonymous online survey if they were able to read English or Malay language. The pharmacist explained the study details to the patient and obtained their consent. The patients were instructed to scan a QR code using their smartphones to access the study information sheet followed by an online survey about their perception regarding counselling received from the CPs about the use of topical corticosteroids. The participants were instructed to complete the survey after leaving the pharmacy premises.

Data analysis

IBM SPSS (version 25) was used to analyse the data. Descriptive statistics were calculated, and the distribution of scores was checked for normality. Bivariate comparisons of CPs counselling practice score on TCS use were done with demographic factors of CPs, time taken for preparation and conduct of counselling on TCS use, perceived barriers to counselling and delivery time, training about ADE and the action taken if ADE to TCS was experienced by the patient. The bivariate comparisons that were significant at $p < 0.25$ were included in the multivariate analyses. CPs perceived patient knowledge of TCS

scores, and TCS counselling practice scores were the outcome variables. Multiple linear regression analysis was conducted to identify the factors associated with the CPS counselling practice score. Adjusted odds ratios and the 95% confidence interval (CI) were estimated ($p < 0.05$).

The International Medical University Joint Committee for Research and Ethics approved this research (Project ID number: MSPH I/2021(04)) on the 14th of February 2021. An informed consent was sought from the CPS to participate in the survey and the procedures were followed as per the declaration of Helsinki.

Results

Response rates and characteristics of CPs

Questionnaires were sent to 364 participants, out of whom 215 completed the questionnaire. The response rate was 70% and all responses were complete. Table 1 shows demographic and other characteristics of the CPs. Out of 215 respondents who completed the survey, 155 (72.1%) were females and 60 (27.9%) were males. The median age of participants was 29 years (IQR 28-31), with a median of 3 (2-5) years of experience as a community pharmacist. Most participants were of Chinese ethnicity (70.7%), worked in chain pharmacies (65.5%), were full-time employees (87.0%), had a bachelor's degree (94.4%), and indicated that they had been trained in adverse drug events (ADEs) (82.3%) (table 1).

Pharmacy practices related to TCS

About 97% responded that "14 days or less" as maximum duration for TCS treatment and 85.6% of the CPS correctly three topical corticosteroids in decreasing order of their potency. About 1 in 10 CPS (10.2%) accurately identified scenarios that necessitate medical referrals. 98.1% of CPS perceived that "pharmacist's explanation" and 90.2% "Internet" as patient's main source of information on TCS. Respondents rated steroid-only topical corticosteroid as most sold compared to other steroid-combination products, followed by steroid-antibiotics or steroid-antifungals, steroid-keratolytic, and steroid-other combination. Pharmacists ranked medication misuse and medication characteristics, such as potency of topical corticosteroids, as the most common cause of adverse drug events; followed by patient characteristics, (patient's age), and medication overuse. Dry skin and skin irritation were the most reported adverse drug event, followed by skin discolouration and skin infections. When patients contacted community pharmacists about adverse drug events caused by topical corticosteroids, 79.5% recommended them to discontinue the medication and advised them to see a doctor. Additionally, 76.7% of respondents indicated they would recommend treatment re-trial following a medication review and patient re-education. Only 27.0% of participants would report the event to the National Pharmaceutical Regulatory Agency (NPRA).

Dispensing characteristics of TCS, counselling about TCS use and barriers

Table 2 shows dispensing characteristics and barriers to counselling about TCS. Participating pharmacists estimated 60% (IQR 30.0 – 90.0) of topical corticosteroid sales are non-prescription, with half (50%, IQR 30.0 – 70.0) were sales by pharmacist's recommendation. Pharmacists estimated spending a median of 5.0 minutes (IQR 5.0 – 8.0) to prepare for counselling. Counselling a patient on a prescription TCS took a similar median time of 5.0 minutes. The frequency of explaining to the patient about various aspects of TCS use are shown in table 3. The CPs most of the time explained that the medication was a TCS (86%), and its frequency and duration of use (>90%); however, information about potency, method of application including strength (dose), side effects were not explained most of the time to the patients (<50%) (table 3). A total 153 of 215 respondents reported of at least two barriers. Among 306 responses received patient's negative perception towards TCS (65.4%), lack of time for counselling (49.7%), lack of counselling material (40.5%), and presuming patients already knew about TCS (30.7%) were commonly selected barriers by the CPs (table 2).

Factors associated with patients' knowledge on TCS and counselling practice scores

Table 4 shows the bivariate comparisons of CPs counselling practice score with demographic factors and factors related to counselling about TCS. The scores were higher among younger CPs, those trained in ADE, those who spent more time preparing for counselling and counselling patients, those who perceived greater barriers to counselling and those with a higher knowledge score. Counselling practice score was associated with age, training on adverse drug events, time spent on counselling, knowledge, and perceived barriers (<0.05). On multivariate analyses, counselling practice score decreases with age with the odds reducing by 0.86 times for each one-unit increase in age ($p = 0.001$). Practice scores are also reduced by 0.11 times for each one-unit increase in topical corticosteroid supply by pharmacists' recommendation ($p = 0.037$). Counselling practice scores are increased by 42% ($p = <0.001$) and 4% ($p = 0.047$) for time spent for counselling for prescription and non-prescription topical corticosteroid respectively (table 5).

Patient's Experience Receiving Counselling from Community Pharmacists

A total of 30 patient responses were obtained. Nineteen respondents (63.3%) were female, 15 were of Malay ethnicity while 11 (36.7%) were Chinese and 16 respondents (53.3%) were prescribed a steroid only preparation while 12 were prescribed a combination of a steroid with an antimicrobial. Twenty (66.7) purchased TCS for their own use. Out of 30 patient respondents who completed the questionnaire survey, 11 (36.7%) were males and 19 (63.3%) were females. The mean age of patient participants was 43.3 years (SD= 10.9) and half the participants were of Malay ethnicity (50%). More than half of patients purchased steroid-only topical corticosteroids (53.3%), and 66.7% of patients purchased the medication for their own use. The content of counselling received by patients from a community pharmacist was also surveyed (Table 6). Patients were asked if they received specific counselling about their purchased medication from a pharmacist, such as skin conditions that the medication should not be used on, potency, dosage, frequency, and duration, and information about potential adverse events. All patients were informed of the frequency and duration of application of medication, and that the product purchased is a topical corticosteroid. Most patients were also counselled on the potency of the TCS, how to apply the prescribed medication, and dosage and potential side effects of the topical steroid. However, less than half were counselled on the appropriate action to take when an adverse drug event occurs, and the storage and use of leftover medication.

Discussion

Counselling practice scores were shown to be significantly associated with age, education level of the pharmacist and time spent preparing and delivering counselling. In the current study, CPs had sufficient knowledge to conduct patient counselling and perceived themselves to be information providers for patients. Congruent to prior research by Kang et al., there was a significant association between knowledge of the patient as perceived by the CPs and counselling practice scores [11]. A greater counselling practice score was associated with a greater awareness of barriers regarding counselling. Additional characteristics associated with counselling practice scores, such as age, work status, supply of TCS according to pharmacists' recommendation, and time providing counselling were noted in this study.

Socio-demographic characteristics and counselling behaviours

The age of CPs had a significant association with their counselling practice scores. Counselling practice scores decreased with increasing age. This observed is to be anticipated, since younger pharmacists are typically recent graduates who have been exposed to a patient-centred pharmacy curriculum emphasising effective communication skills. As a result, they would have developed greater knowledge and skills to counsel patients comprehensively regarding the treatment and management of minor ailments [18]. The supply of TCS on pharmacists' recommendation also showed significant association with counselling practices. This is consistent with the assumption pharmacists' have of patients' understanding of TCS, and they may not provide exhaustive information on side effects to prevent the development of steroid phobia [19]. CPs who had been trained in ADE reporting had higher counselling practice scores and the scores were also higher among those who reported greater barriers to counselling. Reporting ADE and counselling are part of the extended roles of CPs and receiving training in ADE reporting may also have created a positive attitude toward patient counselling.

In this study only 27% of CPs mentioned that they would report an ADE/ADR. ADR reporting is influenced by several factors. In Korea it was seen that knowledge of spontaneous reporting, prior experience of ADRs and less concerns about barriers to reporting were associated with higher reporting rates [20]. A study conducted in four northern states in Malaysia found that only 12.9% of pharmacists had reported an ADR and barriers identified included lack of knowledge on how to report an ADR, non-availability of reporting forms and lack of knowledge regarding where the reports were to be sent [21]. However, the CPs had a positive attitude toward ADR reporting.

Perceived knowledge of Topical Corticosteroids and Counselling Behaviours

The pharmacists who took part in this study perceived patients to have good knowledge about TCS. Time spent to deliver counselling had significant association with counselling practice scores as well. These findings support a previous study's conclusion that pharmacists who spend adequate time with patients provide better medication counselling [10]. Participating pharmacists also reported a lack of time for counselling as a barrier to providing counselling. Research postulated that the more time a pharmacist had to advise patients on the use of TCS, the more positive were the pharmacists' views towards information provision [19].

Most participating pharmacists reported experiencing barriers to counselling. The biggest barrier was patients' negative perceptions of TCS, followed by the lack of time for counselling. This result is consistent with studies conducted among CPs in Korea [11]. Steroid phobia has been extensively researched in dermatological conditions, and it is prevalent among both patients and caregivers [22]. The correlation between steroid phobia and the aversion to using TCS is well established, and this may lead to non-adherence, insufficient therapy, and treatment failure [19].

In this study, counselling by community pharmacists' often included information on the "expected effectiveness", "potency", "dosage", and "frequency of application" regardless of their perception of patient comprehension. If the pharmacist considers that a patient may be unfamiliar with information such as "it is a topical corticosteroid", "action to take in case of an adverse drug event", "duration of application", and "storage and use of remaining medication following treatment completion", it was provided. These findings are almost identical to those of Kang et al., who hypothesised that counselling information is impacted by pharmacists' assumptions about patients' knowledge rather than real patient needs [11].

Poor knowledge about the use of TCS in atopic dermatitis was noted among Australian pharmacists and these appear to be modifiable through targeted education provided by a dermatologist [23]. Better communication between pharmacists and dermatologists can ensure patients receive accurate and unified counselling on TCS according to a study conducted in Wisconsin, United States [24]. In a study conducted in Pakistan, patient characteristics, free availability of TCS, and lack of physician-pharmacist coordination were regarded as major factors promoting misuse of TCS and lack of time and of counselling materials were mentioned as significant barriers to counselling [25]. In Japan, due to the lack of adequate knowledge pharmacists provided incorrect advice about the fingertip unit as a unit of TCS dose in atopic dermatitis [26]. These studies show problems with knowledge about TCS counselling among pharmacists in different countries.

To the best of our knowledge, this is the first study to incorporate patients' experience receiving counselling from a community pharmacist on the use of TCS in Malaysia. The results show that patients and pharmacists agreed on the information provided and the quality of counselling. Most patients indicated they received counselling on the potency, dosage, and frequency of the TCS purchased. This was consistent with the pharmacists' self-reported behaviours of information provision. These results differ from a previous study by Teixeira et al. showing inconsistencies between pharmacists' self-reported behaviour and patients' claims where only 1 in 4 patients was informed of the dosage and 1 in 3 were provided with information about the duration of use of the medication prescribed [12]. Pharmacists are more likely to provide information about adverse effects of TCS if they perceive that patient are unaware but withhold further information to avoid the development or perpetuation of steroid phobia [11, 19].

This was among the few studies conducted on counselling by CPs regarding TCS. CPs perception regarding patient knowledge of TCS was also explored. This study also has several limitations. First, this study was conducted among CPs in Selangor, Kuala Lumpur, and Putrajaya only. Hence, the results may not be generalizable to all CPs in Malaysia. Larger scale, and nationwide studies on community pharmacists from urban, suburban, and rural places of practice

would be beneficial. Second, this study does not evaluate the clinical outcomes of patients, which would examine the influence of pharmacists' counselling in the treatment of dermatological conditions. The third limitation was the small sample of patients and their selection being dependent on the pharmacists themselves, resulting in a Hawthorne effect. This was a result of the strict social distancing measures during the Coronavirus pandemic. Lastly, since this was a self-administered questionnaire, social desirability and self-reported biases may impact responses. However, internal consistency of data collected and the parallels in results with earlier studies are significant, suggest that the findings are reliable.

Conclusions

The CPS counselling practices about the use of topical corticosteroids mainly provided information about frequency and duration of application of TCS. Age of CPs, counselling preparation and delivery time were significantly associated with counselling practice. Continuing education and hands-on training and a greater collaboration between different healthcare providers are needed to improve medication counselling provided by the community pharmacists.

Abbreviations

ADE Adverse Drug Events

ADR Adverse Drug Reaction

CPS Community Pharmacists

IQR Inter Quartile Range

TCS Topical Corticosteroids

Declarations

Ethics declarations Ethics approval and consent to participate

This study was approved by the International Medical University Joint Committee on Research and Ethics. We sought informed consent for participation from both the community pharmacists and patients. All the procedures for ethical approval and consent procedures were followed as per declaration of Helsinki.

Consent for publication

Not applicable.

Data availability

The data associated with the study is available from https://figshare.com/articles/dataset/Knowledge_and_practice_regarding_counselling_of_topical_corticosteroids_among_community_pharmacists/19352540

Acknowledgements

Authors thank all the community pharmacists who participated in the survey.

Funding

None

Authors contribution

ADN, PRS, and CTS conceptualized the study. ADN collected the data. ADN, and CTS analysed and interpreted the data. ADN, PRS and CTS co-drafted the manuscript. All authors provided critical feedback comments and did revisions to the draft manuscript, read and approved the final manuscript.

Acknowledgements

Authors acknowledge the participants of this study for their help in completing the survey questionnaire

Competing interests

The authors declare that they have no competing interests.

References

1. Hamidi N, Tan YR, Jawahir S, Tan EH. Determinants of community pharmacy utilisation among the adult population in Malaysia: findings from the National Health and Morbidity Survey 2019. *BMC health services research*. 2021;21(1):1–1.
2. Tucker R, Duffy J. The role of community pharmacists in the management of skin problems. *J Pharma Care Health Sys*. 2014;1(1):105–8.

3. Cheong JY, Hie SL, Koh EW, de Souza NN, Koh MJ. Impact of pharmacists' counseling on caregiver's knowledge in the management of pediatric atopic dermatitis. *Pediatric dermatology*. 2019;36(1):105–9.
4. Strand MA, Miller DR. Pharmacy and public health: A pathway forward. In: *Journal of the American Pharmacists Association* VO – 54 [Internet]. United States; 2014. p. 193. Available from: <https://ezp2.imu.edu.my/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=edsbl&AN=vdc.100053810101.0x000001&site=eds-live>
5. Poisons Act 1952 Act 366 (Sect. 22) [Internet]. *Laws of Malaysia*, S 22 Feb 1, 2019. Available from: <https://msava.org/wp-content/uploads/2019/06/Act-366-9.5.2019.pdf>.
6. First schedule Poisons list. Available from: https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/poisons-list-1.9.2020_1.pdf.
7. Chok M, Fong C, Iyzati A, Shanizza A. Malaysian Statistics on Medicines 2015–2016. Petaling Jaya; 2020 Feb. Available from: <https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/malaysian-statistics-medicines-2015-2016.pdf>.
8. Long CC, Finlay AY. The finger-tip unit—a new practical measure. *Clinical and experimental dermatology*. 1991;16(6):444–7.
9. Devaraj NK, Abdul Manap AH. Topical Corticosteroids in Clinical Practice. *Med J Malaysia*. 2019;74(2):187–9.
10. Stacey SK, McEleney M. Topical Corticosteroids: Choice and Application. *Am Fam Physician*. 2021;103(6):337–43.
11. Kang MJ, Park JH, Park S, Kim NG, Kim EY, Yu YM, et al. Community pharmacists' knowledge, perceptions, and practices about topical corticosteroid counseling: A real-world cross-sectional survey and focus group discussions in Korea. Lu K, editor. *PLoS One* 2020;15(7):e0236797.
12. Teixeira A, Teixeira M, Herdeiro MT, Vasconcelos V, Correia R, Bahia MF, et al. Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments. *Int J Environ Res Public Health* 2021;18(6):1–14.
13. Ali NM, Lee CC, Akhir NS, Izani AS, Leong CT, Muneswarao J, Verma AK. Effectiveness of color and picture labeling in improving the knowledge on topical medications among patients with psoriasis: A randomized controlled trial. *J Pharm Bioallied Sci*. 2020;12(2):201.
14. Amirthalingam S, Verma RK, Appalasamy JR, Barura A, Yi KS. Pharmacists' knowledge and perception of topical antibacterial drug dispensing in community pharmacy setting in Kedah, Malaysia. *Tropical Journal of Pharmaceutical Research*. 2016;15(4):855–60.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. *Int J Surg*. 2014;12(12):1495–9.
16. Issuance of Poison Licence Type A/ B/ E / Permit NaOH. Available from: <https://www.pharmacy.gov.my/v2/en/content/issuance-poison-licence-type-b-e-permit-naoh.html#:~:text=Type%20A%20Licence%3A%20issued%20to,only%20or%20by%20retail%20only>.
17. Pharmaceutical Services Programme. Register of Licences | Pharmaceutical Services Programme [Internet]. 2021. Available from: <https://www.pharmacy.gov.my/v2/en/information/register-licences.html>.
18. Makhoulouf AM, Mohamed Ibrahim MI, Awaisu A, Vyas SK, Yusuff KB. Determinants of community pharmacists' information gathering and counseling practices during the management of minor ailments. *Saudi Pharm J*. 2021;29(9):992–8.
19. Koster ES, Philbert D, Wagelaar KR, Galle S, Bouvy ML. Optimizing pharmaceutical care for pediatric patients with dermatitis: perspectives of parents and pharmacy staff. *International journal of clinical pharmacy*. 2019;41(3):711–8.
20. Lau WM, Donyai P. Knowledge, attitude and advice-giving behaviour of community pharmacists regarding topical corticosteroids. *Pharmacy*. 2017;5(3):41.
21. Elkalmi RM, Hassali MA, Ibrahim MI, Jamshed SQ, Al-Lela OQ. Community pharmacists' attitudes, perceptions, and barriers toward adverse drug reaction reporting in Malaysia: a quantitative insight. *J Patient Saf*. 2014;10(2):81–87.
22. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. *Br J Dermatol*. 2000;142(5):931–6.
23. Smith SD, Lee A, Blaszczyński A, Fischer G. Pharmacists' knowledge about use of topical corticosteroids in atopic dermatitis: Pre and post continuing professional development education. *Australasian Journal of Dermatology*. 2016;57(3):199–204.
24. Millard AN, Stratman EJ. Assessment of Topical Corticosteroid Prescribing, Counseling, and Communication Among Dermatologists and Pharmacists. *JAMA Dermatol*. 2019;155(7):838–3.
25. Shakeel S, Nesar S, Iffat W, Rehman H, Aziz S, Mumtaz T, Hadi H, Jamshed S. Pharmacists' Insights and Behaviors in Preventing the Misuse of Topical Corticosteroids in Pakistan: A Mixed-Method Study. *Cosmetics*. 2021;8(3):72.
26. Oishi N, Iwata H, Kobayashi N, Fujimoto K, Yamaura K. A survey on awareness of the "finger-tip unit" and medication guidance for the use of topical steroids among community pharmacists. *Drug Discoveries & Therapeutics*. 2019.

Tables

Table 1

Demographic characteristics of the community pharmacists who participated in the study

Variable	Frequency,	%
N= 215		
Age (median and IQR years)	29.0 (28 - 31)	
Gender		
Male	60	27.9
Female	155	72.1
Ethnicity		
Chinese	152	70.7
Malay	26	12.1
Others	37	17.2
Pharmacy location		
Selangor	126	58.6
Kuala Lumpur and Putrajaya	89	41.4
Type of Pharmacy		
Pharmacy chain	141	65.5
Independent Pharmacy	74	34.4
Work Status		
Full-time	187	87.0
Part-time	28	13.0
Education level		
Degree	203	94.4
Post-graduate	12	5.6
Trained in adverse drug events (ADE)		
Yes	177	82.3
No	38	17.7

Table 2

CP reported monthly sales, dispensing practices, and barriers to counseling

Dispensing and sales of TCS (monthly average)	Median (IQR)
Non-prescription TCS (%)	60.0 (30.0-90.0)
Pharmacist's recommendation (%)	50.0 (30.0-70.0)
Counseling preparation time (minutes)	5.0 (5.0-8.0)
Time spent counseling for each prescription TCS (minutes)	5.0 (4.0-10.0)
Time spent counseling for each non-prescription TCS (minutes)	5.0 (3.0-8.0)
Barriers	
	Frequency (%)
Patient's negative perception of topical corticosteroids	100 (65.4)
Lack of time for counseling	76 (49.7)
Lack of counseling material	62 (40.5)
Presume patients already know about topical corticosteroids	47 (30.7)
Doctor's negative perceptions of pharmacists' counseling	21 (13.7)

Table 3 Frequency of explaining the TCS use by the CPs and barriers to counseling

Counseling aspects of TCS use	Most of the time	Half the time
How to use- frequency of application in a day	92.1	7.0
That it is a topical corticosteroid	90.2	7.9
How to use- duration of treatment	86.5	11.6
How to use- choice of formulation (ointment, cream, lotion, etc.)	50.7	33.0
Adverse drug events	49.8	41.4
Skin conditions and diseases where TCS should not be used	47.0	38.1
Expected efficacy and effectiveness	44.7	47.4
Strength (potency)	44.7	44.7
Symptoms to look out for in an adverse drug event	19.5	47.9
How to use- dosage	55.3	32.1
Precautions for storage and application of leftover topical corticosteroids after treatment completion	13.0	36.3

Table 4

Bivariate comparison of the CP counseling practice score on TCS use with demographic, practice-related factors.

	Mean practice score (SD)	Correlation coefficient	p-value
Age (years)[€]		-0.18	0.009*
Sex[¶]			
Male	14.72 (3.27)		0.062
Female	15.63 (3.15)		
Ethnicity[¶]			
Chinese	15.15 (3.38)		0.145
Malay	15.39 (2.80)		
Others	16.30 (2.56)		
Pharmacy location[¶]			
Selangor	15.22 (3.29)		0.415
Kuala Lumpur & Putrajaya	15.58 (3.08)		
Type of Pharmacy[¶]			
Pharmacy chain	15.46 (3.11)		0.575
Independent Pharmacy	15.20 (0.39)		
Work status[¶]	15.44 (3.27)		
Part-time	14.89 (2.70)		0.397
Full-time	15.44 (3.27)		
Experience as a community Pharmacist (years)[€]		-0.09	0.188
Education[¶]			
Degree	15.45 (3.13)		0.287
Post-graduate	14.08 (4.17)		
Trained in ADE[¶]			
No	14.10 (3.70)		0.007
Yes	15.64 (3.03)		
Supply of TCS by pharmacist's recommendation (%)[€]		0.14	0.037
Counseling preparation time (mins)[€]		0.27	<0.001
Time spent counseling about prescription TCS (mins)[€]		0.38	<0.001
Time spent counseling about non-prescription TCS (mins)[€]		0.32	<0.001
Perceived barriers to counselling[¶]			
No	14.40 (3.47)		0.004
Yes	15.77 (3.01)		
Experienced any patients' who reported ADE[¶]			
No	15.40 (3.31)		0.838
Yes	15.30 (2.90)		
Knowledge score[§]		0.14	0.043

[¶] Independent Samples t-test, [¥] One-way analysis of variance, [€] Spearman's rank correlation coefficient

Table 5

Multivariate analyses of factors associated with counseling practice scores on TCS use.

	Adjusted Odds Ratio (95% CI)	p-value
Age (years)	0.86 (0.78 – 0.94)	0.001
Trained in ADE		
No	1	0.066
Yes	0.39 (0.14 – 1.07)	
Supply of TCS by pharmacist's recommendation (%)	0.11 (0.02 – 0.61)	0.037
Counseling preparation time (mins) [€]	1.15 (1.01 – 1.33)	0.060
Time spent counseling about prescription TCS (mins)	1.42 (1.23 – 1.64)	<0.001
Time spent counseling about non-prescription TCS (mins)	1.04 (0.82 – 1.25)	0.083
Perceived barriers to counseling		
No	1	0.171
Yes	1.92 (0.75 – 4.85)	
Knowledge score	1.31 (0.77 – 2.21)	0.318

Table 6

Content of counseling received by patients (N=30)

Counseling content received	Frequency	Percentage
It is a topical corticosteroid	30	100
Skin conditions where the topical corticosteroid should not be used	20	66.7
Potency (strength)	24	80.0
Dosage	28	93.3
Frequency	30	100
Duration	30	100
Potential adverse effects of the topical corticosteroid	21	70
What to do when an adverse drug event occurs	14	46.7
Storage and use of leftover medication	11	36.7

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Patientquestionnaire.docx](#)
- [QuestionnairePharmacist.docx](#)